Let’s build a healthier future, together! By combining our unique strengths, we are redefining healthcare through sustainable action and innovation. For a behind-the-scenes look, check out this video to see how we at Roche are making personalized health care a reality.
The mySugr GmbH was acquired by Roche in 2017 and our Vienna office is one of Roche's global sites. You will be located here, in the heart of Vienna, no matter if you work on a mySugr®, Accu-Chek®, navify® or any other Roche product or solution. You can read more about the history of mySugr & Roche here .
Here’s what we're looking for:
We, the Digital Biomarker and Remote Patient Management (dBM & RPM) Chapter in Roche Information Solutions, are an integrated team of scientists, technologists, data analysts and operationalization experts, that leverages mobile technologies like smartphones and wearables to collect objective and continuous sensor data from patients in clinical trials and clinical care.
We co-create innovative digital biomarker concepts for sensitive and meaningful drug development endpoints, implement them in technology solutions, develop health related outcome measures, seek community- and regulatory acceptance of corresponding endpoints and provide end-to-end services to Biopharma companies and research institutes for the collection and analysis of digital endpoint data in clinical trials. Moreover, we are establishing the scientific foundations for disease monitoring and screening solutions in clinical practice.
This role will focus in particular on our Navify digital biomarker solutions for Parkinson’s and Huntington’s disease - see https://navifyresources.com/digital-biomarkers/ for a description of the products.
The following publications provide a good overview of the scientific foundations of the products:
Giboin, L.S., Simillion, C., Rennig, J., Bamdadian, A., Kinsella, F.C., Smith, A.V., McColgan, P., Lindemann, M., Lipsmeier, F., Wild, E.J. and Dorn, J., 2025. A digital motor score for sensitive detection of progression in Huntington’s disease. Brain, p.awaf127.
Taylor, K.I., Lipsmeier, F., Scelsi, M.A. et al. Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab. npj Digit. Med. 8, 365 (2025).
Your upcoming mission:
Provide scientific guidance for data analysis projects
Support interactions with customers during the pre- and post-sales phases
Contribute to the communication of scientific results at conferences, in white-papers, and in peer-reviewed publications.
Develop scientific core messages for product marketing
Your profile:
University degree (Ph.D. or equivalent) in Life Sciences or related field with a minimum of 5 years related experience in the pharmaceutical and digital health industry
#J-18808-Ljbffr
Digital Biomarker Scientist Parkinson s Disease / Huntington s Disease - Freelancer - roche in Wien Arbeitgeber: OpenTalent
Qwello.eu ist ein hervorragender Arbeitgeber, der die Zukunft der E-Mobilität aktiv mitgestaltet. In einem dynamischen und innovativen Umfeld bieten wir nicht nur spannende Projekte im Bereich Embedded Engineering, sondern auch zahlreiche Möglichkeiten zur persönlichen und beruflichen Weiterentwicklung. Unsere offene Unternehmenskultur fördert Teamarbeit und Selbstorganisation, während wir gleichzeitig auf eine nachhaltige Produktion und strenge Zertifizierungsstandards achten.
